Related Experiment Videos
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease
J K French1, H D White, S C Greaves
1Cardiology Department, Green Lane Hospital, Auckland.
Insights
Simvastatin effectively lowers cholesterol in patients with coronary heart disease, significantly reducing LDL cholesterol without major adverse effects. This lipid-lowering therapy shows promise for safe, short-term use in this patient group.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Hypercholesterolaemia is a significant risk factor for coronary heart disease (CHD).
- Patients with CHD, particularly those post-coronary artery bypass grafting (CABG), often require effective lipid-lowering therapies.
- Statins are a cornerstone of treatment for dyslipidemia.
Purpose of the Study:
- To evaluate the efficacy and safety of simvastatin in patients with coronary heart disease.
- To assess the impact of simvastatin on lipid profiles, including total cholesterol, LDL, and HDL cholesterol.
- To determine the short-term tolerability of simvastatin in this specific patient population.
Main Methods:
- A study involving 26 patients diagnosed with coronary heart disease.
- Twenty of the participants had previously undergone coronary artery bypass grafting.
- Lipid profiles (total, LDL, HDL cholesterol, apoproteins A1 and B) were measured before and after simvastatin treatment.
Main Results:
- Simvastatin significantly reduced total cholesterol by 38% (8.3 to 5.1 mmol/L) and LDL cholesterol by 48% (6.3 to 3.3 mmol/L) (p < 0.001).
- High-density lipoprotein (HDL) cholesterol showed a non-significant increase from 1.19 to 1.24 mmol/L.
- Changes in apoproteins A1 and B correlated with HDL and LDL cholesterol levels, respectively.
- No clinically significant adverse effects were reported during the short-term treatment period.
Conclusions:
- Simvastatin is an effective therapy for lowering lipid levels in patients with coronary heart disease.
- The drug is safe for short-term use in patients with CHD, including those who have had CABG.
- Simvastatin represents a viable option for managing hypercholesterolaemia in patients with established cardiovascular disease.
Abstract:
The efficacy of simvastatin therapy for hypercholesterolaemia was evaluated in 26 patients with coronary heart disease, 20 of whom had undergone coronary artery bypass grafting. Simvastatin reduced total- and low-density lipoprotein (LDL) cholesterol from 8.3 to 5.1 (38%) and 6.3 to 3.3 mmol/L (48%) respectively, p less than 0.001; high-density lipoprotein (HDL) cholesterol increased from 1.19 to 1.24 mmol/L, p = NS. The changes in apoproteins A1 and B paralleled those of HDL- and LDL-cholesterol. There were no clinically important adverse effects. We conclude that simvastatin is effective lipid lowering therapy and can be used safely, in the short term, in patients with coronary heart disease.